Radar · Life Sciences in Israel
Best Life Sciences Companies in Israel
The 1290 best Life Sciences companies in Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Insightec.
By Rohit KhannaTrends & Stories
1290companies tracked
$8.5Bdisclosed funding
2unicorns
402have raised
Israel's Life Sciences sector is one of the most densely funded biotech ecosystems on the planet, and this directory ranks the best companies building inside it, ordered by disclosed equity funding and recent momentum. We're tracking 1,290 companies here, with $8.5B in total disclosed funding across the cohort.
The numbers at the top are telling. BlueWind Medical leads at $64M raised, followed by Ossio at $61M and BiomX at $56M, all operating in a global life sciences market growing at 10.2% CAGR. Hot themes right now are stem cell banking, cell-based therapies, diagnostic biotechnology, and gene delivery systems, which tracks with what you're seeing in deal flow globally, from SAI Life Sciences filing for IPO to strategic acquisitions deepening API capabilities. Digital health adjacent to this sector is moving fast too, with median app install growth running at roughly 43% YoY across healthcare and life sciences platforms. So what's the real signal? Investors like Pontifax and The Trendlines Group are doubling down, and the two unicorns sitting inside this cohort suggest Israel's life sciences story isn't slowing anytime soon.
Sources & further reading
- Aurobindo Pharma, Lupin to Natco Pharma: Why is Nifty Pharma Index nosediving to
- Molecular Pharming Market Growth Driven by Bio Farming Investment and Innovative
- Iran-US war impact may push up medicine prices in India
FLIAR INTELLIGENCE · LIFE SCIENCES × ISRAEL
Our analysis of 50 Life Sciences companies
$2.2b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
50companies analysed
75%cloud-native stacks
2024funding peak (by rounds)
1unicorns
2014median founding year
354kcombined LinkedIn audience
30%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Israel
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Insightec 🦄 Provider of MR-interfaced ultrasound technology-based device for cancer and neurology 89Patents top 17%Moat top 17%Funding top 18%Innovation top 24% All 10 signals ▾Patentstop 17% Moattop 17% Fundingtop 18% Innovationtop 24% Talenttop 28% Markettop 29% Growthtop 32% Techtop 33% Globaltop 33% Newsbottom 21% Patents: 390 patents matched (strict assignee match) · 133 filings since 2022 vs 124 in 2017-21 Moat: Editorial + unicorn rating 9/10 · IP moat: 390 patents rank vs industry peers · Fliar Intelligence Index 89/100 | $574M | 24 mo ago | Series G | 144 | 1999 | — | 390 patents Image-guided focused ultrasound therapy with real-time monitoring and skull aberration correction | 1 award |
| 2 | Magenta Medical Venous catheter-based therapy for ADHF 57Patents top 17%Innovation top 21%Funding top 26%Moat top 28% All 10 signals ▾Patentstop 17% Innovationtop 21% Fundingtop 26% Moattop 28% Producttop 31% Markettop 45% Globalbottom 43% Growthbottom 42% Techbottom 34% Newsbottom 21% Patents: 440 patents matched (strict assignee match) · 291 filings since 2022 vs 129 in 2017-21 Innovation: 440 patents (top 6% of patent-holders) · 291 filings since 2022 vs 129 in 2017-21 rank vs industry peers · Fliar Intelligence Index 57/100 | $183M | 22 mo ago | Series D | 63 | 2012 | — | 440 patents Implantable ventricular assist devices and low-profile blood pump technologies for cardiac support | — |
| 3 | Augmedics Provider of an augmented reality guidance system for surgery 69AI top 15%Product top 21%Funding top 27%Moat top 28% All 12 signals ▾AItop 15% Producttop 21% Fundingtop 27% Moattop 28% Innovationtop 34% Patentstop 36% Growthtop 45% Techtop 45% Markettop 48% Talentbottom 49% Globalbottom 37% Newsbottom 21% AI: Holds AI/ML patents (G06N-family CPC) Product: 5 distinct product lines · Company stage: Series D rank vs industry peers · Fliar Intelligence Index 69/100 | $143M | 35 mo ago | Series D | 109 | 2014 | — | 190 patents Image-guided spinal surgery visualization and instrument navigation systems | — |
| 4 | CytoReason Discovering immune system based drugs by biological data analytics 62Funding top 25%Product top 25%Innovation top 34%Growth top 35% All 11 signals ▾Fundingtop 25% Producttop 25% Innovationtop 34% Growthtop 35% Talenttop 38% Partnerstop 41% Markettop 47% Moatbottom 48% Techbottom 40% Globalbottom 36% Newsbottom 18% Funding: Raised $130M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Product: 6 distinct product lines · Company stage: Series C rank vs industry peers · Fliar Intelligence Index 62/100 | $130M | 23 mo ago | Series C | 133 | 2016 | — | — | 2 partnerships |
| 5 | Scopio Labs Developer of digital imaging platforms for hematology 83AI top 15%Funding top 19%Product top 21%Moat top 28% All 11 signals ▾AItop 15% Fundingtop 19% Producttop 21% Moattop 28% Techtop 29% Patentstop 31% Innovationtop 34% Growthtop 35% Markettop 45% Globalbottom 43% Newsbottom 17% AI: Holds AI/ML patents (G06N-family CPC) Funding: Raised $115M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 83/100 | $115M | 10 mo ago | Series D | 124 | 2014 | — | 72 patents Automated digital microscopy imaging and slide handling for high‑throughput pathology | 1 launch · 1 award |
| 6 | Orasis Pharmaceuticals Developer of reformulated eye drops for the treatment of Presbyopia 32Funding top 24%Moat top 32%Product top 40%Talent top 41% All 11 signals ▾Fundingtop 24% Moattop 32% Producttop 40% Talenttop 41% Patentstop 47% Globalbottom 45% Techbottom 44% Innovationbottom 40% Growthbottom 40% Marketbottom 34% Newsbottom 21% Funding: Raised $111M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 31 patents rank vs industry peers · Fliar Intelligence Index 32/100 | $111M | 20 mo ago | Series D | 24 | 2015 | — | 31 patents Formulating and delivering ophthalmic drugs for eye disease treatment. | 1 launch |
| 7 | PolyPid Technology platform enabling controlled and prolonged release of any Active Pharmaceutical Ingredient (API) 60Funding top 18%Moat top 29%Patents top 38%Tech top 39% All 9 signals ▾Fundingtop 18% Moattop 29% Patentstop 38% Techtop 39% Innovationtop 46% Growthtop 48% Markettop 50% Globaltop 50% Newsbottom 40% Funding: Raised $96.7M across 10 rounds · 10 rounds over 14 yrs (0.7/yr) Moat: Editorial + unicorn rating 6/10 · IP moat: 138 patents rank vs industry peers · Fliar Intelligence Index 60/100 | $97M | 12 mo ago | Public | 69 | 2008 | 3 signals ▼50% Earnings · Leadership | 138 patents Patents concentrated in health & consumer products | 1 launch |
| 8 | ForSight Robotics Provider of an AI-based ophthalmic surgical robot for healthcare professionals 76Innovation top 26%Patents top 27%Growth top 28%Moat top 28% All 10 signals ▾Innovationtop 26% Patentstop 27% Growthtop 28% Moattop 28% Fundingtop 29% Techtop 45% AItop 45% Marketbottom 47% Globalbottom 40% Newsbottom 18% Innovation: 70 patents (top 39% of patent-holders) · 70 filings since 2022 vs 0 in 2017-21 Patents: 70 patents matched (strict assignee match) · 70 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 76/100 | $65M | 11 mo ago | Series B | 50 | 2020 | — | 70 patents Robotic microsurgery hardware: control, input, magnetic sensing, kinematics, and sterile drapes. | 2 awards |
| 9 | BlueWind Medical Developer of neurostimulation device for the treatment of overactive bladder 50Patents top 39%Funding top 40%Innovation top 43%Tech top 46% All 9 signals ▾Patentstop 39% Fundingtop 40% Innovationtop 43% Techtop 46% Moattop 47% Markettop 50% Talentbottom 49% Globalbottom 40% Newsbottom 22% Patents: 73 patents matched (strict assignee match) · 23 filings since 2022 vs 38 in 2017-21 Funding: Raised $64.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $64M | 1 mo ago | Series B | 95 | 2010 | — | 73 patents Wireless implantable neurostimulation devices and antenna designs for neuromodulation therapy. | 1 launch |
| 10 | Ossio Bone regeneration biocomposite 72Funding top 25%Growth top 28%Moat top 29%Patents top 31% All 10 signals ▾Fundingtop 25% Growthtop 28% Moattop 29% Patentstop 31% Innovationtop 35% Techtop 37% Talenttop 38% Newstop 45% Markettop 50% Globalbottom 37% Funding: Raised $61.4M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 72/100 | $61M | 4 mo ago | Series C | 74 | 2014 | — | 128 patents Orthopedic suture anchors and bioresorbable fiber‑reinforced implant technologies | 1 launch · 1 partnership · 1 expansion |
| 11 | BiomX Microbiome therapeutics for diseases associated with microbiome dysbiosis 62Funding top 20%Patents top 34%Growth top 37%Tech top 37% All 9 signals ▾Fundingtop 20% Patentstop 34% Growthtop 37% Techtop 37% Moattop 38% Innovationtop 45% Marketbottom 47% Newsbottom 44% Globalbottom 44% Funding: Raised $56.0M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) Patents: 42 patents matched (strict assignee match) · 24 filings since 2022 vs 18 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $56M | 5 mo ago | Public | 65 | 2015 | — | 42 patents Therapeutic bacteriophage engineering for targeted bacterial infection and gut microbiome modulation | 2 launchs |
| 12 | Alpha Tau Medical Developer of radiotherapy technique for the treatment of solid cancer tumors 62Patents top 14%Innovation top 24%Funding top 26%Moat top 26% All 10 signals ▾Patentstop 14% Innovationtop 24% Fundingtop 26% Moattop 26% Techtop 43% Growthtop 48% Marketbottom 49% Talentbottom 49% Globalbottom 45% Newsbottom 21% Patents: 332 patents matched (strict assignee match) · 279 filings since 2022 vs 53 in 2017-21 Innovation: 332 patents (top 8% of patent-holders) · 279 filings since 2022 vs 53 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $55M | 13 mo ago | Public | 89 | 2015 | — | 332 patents Alpha-emitting radiopharmaceuticals and delivery devices for targeted cancer therapy | 1 partnership |
| 13 | ONCOHOST AI-based oncology therapy plan solution for professionals 64Patents top 27%Moat top 28%Talent top 28%Innovation top 29% All 10 signals ▾Patentstop 27% Moattop 28% Talenttop 28% Innovationtop 29% AItop 30% Fundingtop 31% Techbottom 42% Marketbottom 41% Globalbottom 35% Newsbottom 18% Patents: 55 patents matched (strict assignee match) · 38 filings since 2022 vs 17 in 2017-21 Moat: Editorial + unicorn rating 8/10 · IP moat: 55 patents rank vs industry peers · Fliar Intelligence Index 64/100 | $43M | 13 mo ago | Series C | 48 | 2017 | — | 55 patents AI-driven predictive analytics for personalized cancer treatment response and biomarker identification | 2 job openings |
| 14 | Innoventric Developer of transcatheter solutions for patients with heart diseases 40Funding top 31%Moat top 32%Innovation top 41%Patents top 42% All 7 signals ▾Fundingtop 31% Moattop 32% Innovationtop 41% Patentstop 42% Talentbottom 49% Globalbottom 43% Marketbottom 35% Funding: Raised $41.8M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 37 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $42M | 19 mo ago | Series B | 17 | 2017 | — | 37 patents Percutaneous tricuspid valve repair and implantation devices and storage solutions | — |
| 15 | Brainsway Develoepr of noninvasive neurostimulation treatments for mental health disorders 48Funding top 29%Tech top 35%Patents top 37%Moat top 41% All 11 signals ▾Fundingtop 29% Techtop 35% Patentstop 37% Moattop 41% Innovationtop 43% AItop 45% Globalbottom 49% Talentbottom 49% Growthbottom 47% Newsbottom 24% Marketbottom 23% Funding: Raised $40.5M across 4 rounds · 4 rounds over 12 yrs (0.3/yr) Tech: 59 technologies across 4/8 capability areas · Cloud: Amazon Web Services, Cloudflare rank vs industry peers · Fliar Intelligence Index 48/100 | $40M | 20 mo ago | Public | 1 | 2003 | — | 112 patents Non‑invasive transcranial magnetic stimulation hardware and closed‑loop brain‑stimulation systems | — |
| 16 | BrainStorm Cell Developer ofstem cell therapies for the treatment of neurodegenerative diseases such as ALS, MS, PD 48Funding top 23%Patents top 31%Moat top 38%Innovation top 39% All 10 signals ▾Fundingtop 23% Patentstop 31% Moattop 38% Innovationtop 39% Techtop 39% Talentbottom 49% Marketbottom 41% Growthbottom 40% Globalbottom 39% Newsbottom 23% Funding: Raised $34.9M across 10 rounds · 10 rounds over 14 yrs (0.7/yr) Patents: 75 patents matched (strict assignee match) · Lead CPC: A61K35/28 (+2 more areas) rank vs industry peers · Fliar Intelligence Index 48/100 | $35M | 4 mo ago | Public | 37 | 2000 | — | 75 patents Exosome-based biologics delivering neurotrophic factors for regenerative and pulmonary therapies | — |
| 17 | Vensica Medical Developer of drug delivery catheter for bladder conditions 19Patents top 39%Innovation top 41%Funding top 42%Moat top 44% All 7 signals ▾Patentstop 39% Innovationtop 41% Fundingtop 42% Moattop 44% Globalbottom 43% Techbottom 25% Marketbottom 21% Patents: 27 patents matched (strict assignee match) · 16 filings since 2022 vs 10 in 2017-21 Innovation: 27 patents (top 63% of patent-holders) · 16 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 19/100 | $32M | 18 mo ago | Series B | 5 | 2014 | — | 27 patents Ultrasound‑mediated intravesical drug delivery systems for bladder therapeutics | — |
| 18 | Lutris Pharma Provider of anti-cancer therapy 29Patents top 32%Moat top 32%Funding top 33%Talent top 33% All 9 signals ▾Patentstop 32% Moattop 32% Fundingtop 33% Talenttop 33% Innovationtop 38% Globalbottom 40% Techbottom 31% Newsbottom 18% Marketbottom 17% Patents: 75 patents matched (strict assignee match) · 41 filings since 2022 vs 34 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 75 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $30M | 16 mo ago | Series B | 4 | 2016 | — | 75 patents Topical BRAF kinase inhibitors for EGFR‑related skin toxicities and isoquinoline wound‑healing agents | — |
| 19 | BeaconCure Developer of an AI-enabled statistical analysis platform for biometrics teams 16Moat top 41%Funding top 46%Talent bottom 49%Market bottom 43% All 9 signals ▾Moattop 41% Fundingtop 46% Talentbottom 49% Marketbottom 43% Techbottom 38% Patentsbottom 35% Globalbottom 29% Newsbottom 22% Innovationbottom 21% Moat: Editorial + unicorn rating 7/10 · IP moat: 2 patents Funding: Raised $25.9M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 16/100 | $26M | 17 mo ago | Series C | 27 | 2016 | — | 2 patents Automated validation and verification of tabular summary reports in software systems | 1 launch |
| 20 | Omnix Medical Developer of antimicrobial peptides for the treatment of drug-resistant bacterial infections 42Product top 25%Funding top 30%Tech top 33%Moat top 38% All 8 signals ▾Producttop 25% Fundingtop 30% Techtop 33% Moattop 38% Patentstop 44% Innovationtop 47% Globalbottom 43% Marketbottom 30% Product: 4 distinct product lines · Company stage: Series C Funding: Raised $24.3M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $24M | 8 mo ago | Series C | 17 | 2015 | — | 30 patents Antimicrobial peptide therapeutics targeting infectious diseases and related medical applications. | — |
| 21 | QuantHealth Provider of AI-based clinical trail management tool for researchers 55AI top 30%Funding top 34%Growth top 35%Moat top 39% All 9 signals ▾AItop 30% Fundingtop 34% Growthtop 35% Moattop 39% Techtop 42% Talentbottom 49% Newsbottom 42% Globalbottom 38% Marketbottom 32% AI: Classified as an AI company · Product described with: ai-based Funding: Raised $22.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $22M | 8 mo ago | Series A | 21 | 2020 | — | — | 1 award |
| 22 | MediWound Developer of enzymatic therapeutic solutions for tissue repair and regeneration 60Talent top 33%Funding top 34%Patents top 36%Global top 39% All 10 signals ▾Talenttop 33% Fundingtop 34% Patentstop 36% Globaltop 39% Innovationtop 43% Newstop 43% Markettop 44% Moattop 44% Techtop 47% Growthbottom 47% Talent: 3 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $18.0M across 6 rounds · 6 rounds over 13 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $18M | 23 mo ago | Public | 83 | 2001 | 6 signals ▼33% Earnings · Regulatory · Funding | 111 patents Topical proteolytic enzyme therapies for skin wounds, psoriasis, and skin cancer treatment. | — |
| 23 | RetiSpec Non-invasive eye scanner for early detection of Alzheimer’s Disease. 37Innovation top 38%Funding top 38%Product top 46%Tech bottom 43% All 6 signals ▾Innovationtop 38% Fundingtop 38% Producttop 46% Techbottom 43% Globalbottom 38% Marketbottom 34% Innovation: 2 product lines · Deep-tech classification: Tech Hardware Funding: Raised $17.0M across 3 rounds · 3 rounds over 9 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $17M | 22 mo ago | Series A | 23 | 2015 | — | — | 1 partnership |
| 24 | Collplant Developer of recombinant human collagen for regenerative medicine and aesthetics 53Patents top 22%Funding top 26%Product top 26%Tech top 35% All 10 signals ▾Patentstop 22% Fundingtop 26% Producttop 26% Techtop 35% Moattop 35% Innovationtop 43% Newstop 47% Growthbottom 47% Marketbottom 46% Globalbottom 43% Patents: 170 patents matched (strict assignee match) · 41 filings since 2022 vs 46 in 2017-21 Funding: Raised $16.3M across 11 rounds · 11 rounds over 20 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $16M | 4 mo ago | Public | 73 | 2004 | 5 signals ▼29% Announcements · Earnings · New product | 170 patents Collagen-based soft tissue fillers and degradable implants for medical additive manufacturing. | — |
| 25 | Discure Technologies Developer of minimally invasive, bioelectronic solutions to treat spinal and synovial joint conditions 10Funding top 40%Moat top 45%Talent bottom 45%Global bottom 40% All 7 signals ▾Fundingtop 40% Moattop 45% Talentbottom 45% Globalbottom 40% Patentsbottom 30% Newsbottom 18% Innovationbottom 7% Funding: Raised $16.0M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents rank vs industry peers · Fliar Intelligence Index 10/100 | $16M | 21 mo ago | Series A | — | 2019 | — | 5 patents Computer‑assisted surgical systems and advanced prosthetic load‑bearing implants. | — |
| 26 | Starget Pharma Developer of targeted radiopharmaceuticals technologies to treat solid tumors 32Growth top 35%Talent top 38%Partners top 45%Funding top 48% All 8 signals ▾Growthtop 35% Talenttop 38% Partnerstop 45% Fundingtop 48% Moattop 48% Techbottom 36% Globalbottom 36% Marketbottom 28% Growth: Fresh capital in last 24 mo Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 32/100 | $15M | 4 mo ago | Series A | — | 2019 | — | — | 1 award |
| 27 | Enlivex Pharmaceuticals Developer of autologous and allogeneic cell immunotherapy therapy treatments 55News top 14%Growth top 22%Funding top 32%Moat top 39% All 8 signals ▾Newstop 14% Growthtop 22% Fundingtop 32% Moattop 39% Marketbottom 48% Techbottom 42% Talentbottom 41% Globalbottom 37% News: 15 BI events in 12 mo (of 30 tracked, 9 types) · +650% YoY Growth: Web rank 50,000,000 → 10,000,000 YoY · 2 acquisition/expansion moves in 24 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $15M | 6 mo ago | Public | 77 | 2005 | 15 signals ▲650% Earnings · Buyback · Funding | — | — |
| 28 | Endoron Medical Manufacturer of endovascular suture-like device for cardiovascular treatment 37Moat top 25%Patents top 31%Innovation top 33%Funding top 39% All 7 signals ▾Moattop 25% Patentstop 31% Innovationtop 33% Fundingtop 39% Talentbottom 49% Globalbottom 43% Marketbottom 28% Moat: Editorial + unicorn rating 7/10 · IP moat: 38 patents Patents: 38 patents matched (strict assignee match) · 30 filings since 2022 vs 8 in 2017-21 rank vs industry peers · Fliar Intelligence Index 37/100 | $15M | 23 mo ago | Series A | 10 | 2019 | — | 38 patents Minimally invasive intravascular graft anchoring and tissue fixation catheter technologies | 1 job opening |
| 29 | NanoPass Technologies Microneedles-based device for intradermal delivery 37Innovation top 39%Patents top 39%Funding top 42%Moat top 45% All 8 signals ▾Innovationtop 39% Patentstop 39% Fundingtop 42% Moattop 45% Techtop 48% Talentbottom 49% Globalbottom 43% Marketbottom 30% Innovation: 75 patents (top 36% of patent-holders) Patents: 75 patents matched (strict assignee match) · Latest publication 2016 rank vs industry peers · Fliar Intelligence Index 37/100 | $15M | 23 mo ago | Series C | 16 | 2000 | — | 75 patents Microneedle-enabled intradermal drug delivery systems and associated manufacturing technologies | 3 launchs · 1 partnership |
| 30 | Escala Medical Developing repair device for the treatment of pelvic organ prolapse (POP) 9Funding top 37%Global bottom 36%Market bottom 20% All 3 signals ▾Fundingtop 37% Globalbottom 36% Marketbottom 20% Funding: Raised $13.1M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Global: Investors from 2 countries beyond Israel rank vs industry peers · Fliar Intelligence Index 9/100 | $13M | 11 mo ago | Series A | 5 | 2014 | — | — | — |
| 31 | Nurami Medical Developer of nanofiber and sealant technology for the soft tissue repair 40Moat top 25%Growth top 35%Product top 35%Patents top 37% All 9 signals ▾Moattop 25% Growthtop 35% Producttop 35% Patentstop 37% Fundingtop 41% Innovationtop 42% Globalbottom 40% Techbottom 38% Marketbottom 28% Moat: Editorial + unicorn rating 7/10 · IP moat: 37 patents Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $12M | 15 mo ago | Series C | 16 | 2014 | — | 37 patents Patents concentrated in health & consumer products | 1 launch |
| 32 | Vortex Imaging Medical tech company offering ultrasound imaging devices using UV radiations 24Funding top 35%Moat top 38%Patents top 45%Talent bottom 49% All 8 signals ▾Fundingtop 35% Moattop 38% Patentstop 45% Talentbottom 49% Innovationbottom 48% Techbottom 46% Globalbottom 40% Marketbottom 22% Funding: Raised $12.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents rank vs industry peers · Fliar Intelligence Index 24/100 | $12M | 1 mo ago | Series B | 9 | 2020 | — | 9 patents Advanced full-waveform inversion for high-resolution reflection ultrasound tomography | — |
| 33 | PainReform Specialty pharmaceutical company that develops products for the treatment of pain 32Product top 24%Funding top 34%Growth top 35%Moat top 38% All 11 signals ▾Producttop 24% Fundingtop 34% Growthtop 35% Moattop 38% Newstop 43% Talentbottom 49% Innovationbottom 44% Techbottom 42% Patentsbottom 39% Globalbottom 35% Marketbottom 21% Product: 2 product launch events in 12 mo · 6 distinct product lines Funding: Raised $12.0M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $12M | 11 mo ago | Public | 6 | 2007 | 3 signals New product · Earnings | 22 patents Sustained-release depot formulations for local anesthetics and hydrophobic drugs | — |
| 34 | Neurolief Wearable device for neurological and neuropsychiatric disorders 27Patents top 36%Talent top 38%Innovation top 39%Funding top 46% All 10 signals ▾Patentstop 36% Talenttop 38% Innovationtop 39% Fundingtop 46% Producttop 47% Moattop 47% Globalbottom 35% Marketbottom 28% Techbottom 26% Newsbottom 22% Patents: 55 patents matched (strict assignee match) · 18 filings since 2022 vs 29 in 2017-21 Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 27/100 | $11M | 2 mo ago | Series A | — | 2012 | — | 55 patents Wearable transdermal neurostimulation headsets integrating biosensing for therapeutic monitoring | 1 job opening |
| 35 | Vidac Pharma HK2-VDAC protein interaction disruptors for oncologic and oncodermatologic diseases. 21Product top 36%Growth top 45%Patents top 47%Moat top 47% All 9 signals ▾Producttop 36% Growthtop 45% Patentstop 47% Moattop 47% Innovationbottom 48% Fundingbottom 45% Techbottom 36% Globalbottom 35% Marketbottom 23% Product: 8 distinct product lines · Company stage: Series A Growth: Web rank 10,000,000 → 50,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 21/100 | $10M | 19 mo ago | Series A | 9 | 2011 | — | 44 patents Patents concentrated in health & consumer products | — |
| 36 | Fize Medica Developer of device for monitoring urine 45Talent top 38%Funding top 42%Tech top 42%Growth top 45% All 8 signals ▾Talenttop 38% Fundingtop 42% Techtop 42% Growthtop 45% Moattop 48% Marketbottom 38% Globalbottom 36% Newsbottom 18% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $9.3M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $9M | 2 mo ago | Series A | 27 | 2014 | — | — | — |
| 37 | Butterfly Medical Developer of an implantable device for the treatment of benign prostatic hyperplasia (BPH) 35Moat top 35%Patents top 36%Funding top 37%Talent top 38% All 8 signals ▾Moattop 35% Patentstop 36% Fundingtop 37% Talenttop 38% Innovationtop 39% Globalbottom 43% Techbottom 37% Marketbottom 26% Moat: Editorial + unicorn rating 5/10 · IP moat: 68 patents Patents: 68 patents matched (strict assignee match) · 34 filings since 2022 vs 31 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $9M | 1 mo ago | Acquired | 9 | 2014 | — | 68 patents Urological implants for periurethral tissue support and urinary incontinence treatment | — |
| 38 | Restore Medical Catheter-delivered implant for treatment of congestive heart failure 42Growth top 30%Patents top 38%Funding top 40%News top 40% All 8 signals ▾Growthtop 30% Patentstop 38% Fundingtop 40% Newstop 40% Innovationtop 44% Moattop 47% Globalbottom 35% Marketbottom 29% Growth: Fresh capital in last 24 mo Patents: 30 patents matched (strict assignee match) · 20 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $9M | 11 mo ago | Series B | 9 | 2016 | 3 signals ▲50% Leadership · Funding | 30 patents Vascular implant devices for lumenal constriction and controlled release in arteries | — |
| 39 | Promise Provider of AI-based platform for personalised treatment plans 62Talent top 28%AI top 45%Global top 45%Funding top 47% All 6 signals ▾Talenttop 28% AItop 45% Globaltop 45% Fundingtop 47% Moattop 48% Marketbottom 49% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 62/100 | $8M | 18 mo ago | Seed | — | 2020 | — | — | — |
| 40 | Inspira Developer of a medical device for treating respiratory failure 50News top 24%Growth top 25%Talent top 28%Tech top 42% All 7 signals ▾Newstop 24% Growthtop 25% Talenttop 28% Techtop 42% Fundingtop 47% Marketbottom 33% Globalbottom 25% News: 6 BI events in 12 mo (of 12 tracked, 7 types) · 1 high-value events (IPO/M&A/funding/contracts) in 12 mo Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 50/100 | $8M | 17 mo ago | Public | 21 | 2018 | 6 signals Leadership · Regulatory · Funding | — | — |
| 41 | Cassidy Bio Developer of an AI-powered platform for therapeutic-grade gene editing design 69Talent top 28%AI top 45%Funding top 47%Global bottom 48% All 4 signals ▾Talenttop 28% AItop 45% Fundingtop 47% Globalbottom 48% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-powered rank vs industry peers · Fliar Intelligence Index 69/100 | $8M | 6 mo ago | Seed | — | 2024 | — | — | — |
| 42 | Kamari Pharma Developer of therapies for rare dermatologic diseases and itch conditions 22Moat top 32%Patents top 36%Innovation top 42%Funding top 46% All 6 signals ▾Moattop 32% Patentstop 36% Innovationtop 42% Fundingtop 46% Globalbottom 40% Marketbottom 23% Moat: Editorial + unicorn rating 4/10 · IP moat: 28 patents Patents: 28 patents matched (strict assignee match) · 26 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 22/100 | $8M | 12 mo ago | Series A | 7 | 2018 | — | 28 patents Topical small‑molecule therapeutics for dermatological disorders and skin symptom relief | — |
| 43 | Pepticom Developer of AI-based technology for the discovery of peptide drug candidates 35Moat top 31%Growth top 35%Product top 36%AI top 45% All 10 signals ▾Moattop 31% Growthtop 35% Producttop 36% AItop 45% Techbottom 46% Patentsbottom 45% Fundingbottom 40% Globalbottom 40% Innovationbottom 37% Marketbottom 29% Moat: Editorial + unicorn rating 7/10 · IP moat: 15 patents Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 35/100 | $8M | 17 mo ago | Series A | 18 | 2011 | — | 15 patents Patents concentrated in health & consumer products | — |
| 44 | NurExone Developer of drugs for neurological disorders 40Funding top 36%Tech top 36%Talent top 38%News top 46% All 7 signals ▾Fundingtop 36% Techtop 36% Talenttop 38% Newstop 46% Growthtop 47% Marketbottom 29% Globalbottom 25% Funding: Raised $7.2M across 9 rounds · 9 rounds over 2 yrs (4.5/yr) Tech: 34 technologies across 5/8 capability areas · Cloud: Akamai rank vs industry peers · Fliar Intelligence Index 40/100 | $7M | 3 mo ago | Public | — | 2020 | 7 signals ▼36% Leadership · Earnings | — | 1 partnership |
| 45 | Senseera Provider of liquid biopsy blood tests for cancer diagnosis 35Talent top 28%Funding top 46%Market bottom 37%Global bottom 36% All 4 signals ▾Talenttop 28% Fundingtop 46% Marketbottom 37% Globalbottom 36% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $7.1M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $7M | 17 mo ago | Seed | — | 2020 | — | — | — |
| 46 | Nitinote Surgical Developing non-surgical bariatric medical device 21Talent top 38%Funding top 46%Moat top 48%Global bottom 38% All 6 signals ▾Talenttop 38% Fundingtop 46% Moattop 48% Globalbottom 38% Marketbottom 32% Techbottom 32% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $6.7M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $7M | 17 mo ago | Series B | 20 | 2014 | — | — | 1 partnership |
| 47 | Algocell Provider of AI-powered bioprocess optimization solutions 27Talent top 38%AI top 45%Tech top 49%Funding bottom 42% All 6 signals ▾Talenttop 38% AItop 45% Techtop 49% Fundingbottom 42% Globalbottom 32% Marketbottom 25% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated AI: Product described with: ai-powered rank vs industry peers · Fliar Intelligence Index 27/100 | $3M | 11 mo ago | Seed | — | 2023 | — | — | — |
| 48 | Biobeat Body vitals monitoring solution 48Tech top 34%Growth top 35%Product top 40%Funding top 46% All 7 signals ▾Techtop 34% Growthtop 35% Producttop 40% Fundingtop 46% Moattop 48% Globalbottom 38% Marketbottom 37% Tech: 38 technologies across 5/8 capability areas · Cloud: Amazon Web Services, Cloudflare Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $1M | 5 mo ago | Series B | 29 | 2014 | — | — | 1 expansion |
| 49 | VVT Medical Percutaneous delivery of vascular embolic device for the treatment of varicose veins 37Product top 14%Growth top 35%Funding top 44%Patents top 45% All 9 signals ▾Producttop 14% Growthtop 35% Fundingtop 44% Patentstop 45% Moattop 45% Innovationtop 47% Techtop 48% Globalbottom 37% Marketbottom 24% Product: 4 distinct product lines · Company stage: Post IPO Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 37/100 | $779K | 1 mo ago | Late Stage | 11 | 2007 | — | 78 patents Minimally invasive vascular therapy devices for synchronized injection/aspiration and vein ablation | — |
| 50 | Cell Source Cell therapy treatments for transplantation, cancer treatment and reversal of vital organ disease 7Funding top 48%Global bottom 38%Market bottom 20% All 3 signals ▾Fundingtop 48% Globalbottom 38% Marketbottom 20% Funding: Raised $398k across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Global: Serving 2 countries incl. United States, Israel rank vs industry peers · Fliar Intelligence Index 7/100 | $398K | 5 mo ago | Public | 1 | 2011 | — | — | — |
Top 12 Life Sciences companies in Israel
#1
Series B · Herzliya, Tel Aviv · founded 2010 · 95 employees$64Mraised▾
Series B · Herzliya, Tel Aviv · founded 2010 · 95 employees
Developer of neurostimulation device for the treatment of overactive bladder. The flagship product of the company is "Renova" a wireless device that delivers targeted electric stimulation to the nerve for the treatment of patients with an Overactive Bladder and associated symptoms of urinary urgency and frequency.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Patents
top 39%Funding
top 40%Innovation
top 43%Tech
top 46%Moat
top 47%Market
top 50%Patents: 73 patents matched (strict assignee match) · 23 filings since 2022 vs 38 in 2017-21 · Latest publication 2026
Funding: Raised $64.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (May 2026)
Innovation: 73 patents (top 37% of patent-holders) · 23 filings since 2022 vs 38 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 21k LinkedIn followers — 6.0% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- May 2026Series B$47.8M
- May 2026Conventional Debt—
- May 2022Series B$64M
Founders & team
Investors
ConvaTec, Rainbow Medical
#2
Series C · Caesarea, Haifa District · founded 2014 · 74 employees$61.4Mraised▾
Series C · Caesarea, Haifa District · founded 2014 · 74 employees
Ossio focuses on orthopedic fixation using bone regeneration technology. The company has developed OSSIOfiber, a biocomposite material platform that contains reinforcing synthetic bone fibers and bioabsorbable polymer resin. The fiber provides mechanical strength and the resin provides binding property and promotes bone growth.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 25%Growth
top 28%Moat
top 29%Patents
top 31%Innovation
top 35%Tech
top 37%Funding: Raised $61.4M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) · Last round Conventional Debt (Feb 2026)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 7/10 · IP moat: 128 patents · 9 curated direct competitors tracked
Audience (LinkedIn): 15k LinkedIn followers — 4.3% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 partnerships · 1 expansions (incl. Orthopedics) announced in 12 mo
Funding rounds
- Feb 2026Conventional Debt$50M
- Dec 2024Series C$27.6M
- Oct 2022Series C$38.5M
- Mar 2019Series A$22M
Founders & team
Investors
OCV Partners, Secocha Ventures, MVM, Questa Capital, Courage Capital Management, OrthoVision
Tech stack
Amazon SesAmazon Web ServicesCloudflareCloudflare Bot ManagementCore-JsGoogle Tag Manager
#3
Public · Ness Ziona, Center District · founded 2015 · 65 employees$56Mraised▾
Public · Ness Ziona, Center District · founded 2015 · 65 employees
Microbiome therapeutics for diseases associated with microbiome dysbiosis. The company offers its flagship 3-tier microbiome modulation platform which is an end-to-end platform to identify target bacteria causing microbiome dysbiosis, modulate the microbiome through adding or eradicating bacteria. It also has a GI tract cancer program in prototype discovery and a checkpoint inhibitor program in target discovery.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Funding
top 20%Patents
top 34%Growth
top 37%Tech
top 37%Moat
top 38%Innovation
top 45%Funding: Raised $56.0M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) · Last round Post IPO (Jan 2026)
Patents: 42 patents matched (strict assignee match) · 24 filings since 2022 vs 18 in 2017-21 · Latest publication 2025
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
Audience (LinkedIn): 9k LinkedIn followers — 2.4% of this cohort's audience
Activity (LinkedIn): 2 product launches announced in 12 mo
Funding rounds
- Jan 2026Post IPO$3.3M
- Feb 2025Post IPO$12M
- Mar 2024Post IPO$50M
- Mar 2023Post IPO$1.5M
Investors
Orbimed, Johnson & Johnson Innovation – JJDC, Takeda Ventures, 8VC, Seventure Partners, SBI JI
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#4
Public · Petah Tikva, Central District · founded 2000 · 37 employees$34.9Mraised▾
Public · Petah Tikva, Central District · founded 2000 · 37 employees
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as ALS (Lou Gehrig's disease), Multiple Sclerosis (MS), and Parkinson’s disease (PD). NurOwn is BrainStorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. Its platform technology essentially converts MSCs into living drug delivery systems for NTFS. They use animal models of neurodegenerative diseases, including Parkinson's, Huntington's, ALS, MS, and peripheral nerve injury.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 23%Patents
top 31%Moat
top 38%Innovation
top 39%Tech
top 39%Talent
bottom 49%Funding: Raised $34.9M across 10 rounds · 10 rounds over 14 yrs (0.7/yr) · Last round Post IPO (Feb 2026)
Patents: 75 patents matched (strict assignee match) · Lead CPC: A61K35/28 (+2 more areas)
Moat: Editorial + unicorn rating 5/10 · IP moat: 75 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers — 2.1% of this cohort's audience
Funding rounds
- Feb 2026Post IPO$1M
- Jun 2020Grant (prize money)$500K
- Apr 2020Grant (prize money)$1.5M
- Nov 2019Grant (prize money)$495.3K
Founders & team
Investors
Portalsaude, Israel Innovation Authority, National MS Society, I AM ALS, ALS Association, Iconic Private Equity Partners
Tech stack
AstraCdnjsCloudflareCloudflare Bot ManagementCore-JsDraftpress Hfcm
#5
Acquired · Yokneam Illit, Northern District · founded 2014 · 9 employees$9Mraised▾
Acquired · Yokneam Illit, Northern District · founded 2014 · 9 employees
Developer of an implantable device for the treatment of benign prostatic hyperplasia (BPH). The company's flagship product is a non-surgical device that is different from a conventional surgical treatment that requires a certain level of recovery and involves complications. It claims that the device can be delivered at the comfort of the physician’s office and provides immediate relief.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Moat
top 35%Patents
top 36%Funding
top 37%Talent
top 38%Innovation
top 39%Global
bottom 43%Moat: Editorial + unicorn rating 5/10 · IP moat: 68 patents · 5 curated direct competitors tracked
Patents: 68 patents matched (strict assignee match) · 34 filings since 2022 vs 31 in 2017-21 · Latest publication 2026
Funding: Raised $9.0M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) · Last round Series C (May 2026)
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- May 2026Series C$21M
- Sep 2023Grant (prize money)$2.7M
- Oct 2020Series B$7M
- Jan 2020Angel$2M
Founders & team
Investors
New Rhein, The University of California, MassChallenge, EIC Fund, Europa, Junson Capital
Tech stack
WordpressMysqlPhpCyberchimps ResponsiveContact Form 7Yoast Seo
#6
Series B · Ramat Gan, Tel Aviv District · founded 2020 · 9 employees$12Mraised▾
Series B · Ramat Gan, Tel Aviv District · founded 2020 · 9 employees
Medical tech company offering ultrasound imaging devices using UV radiations. It uses hypercompute imaging technology for ultrasound imaging modality, based on geophysics algorithms and computational software interface with GPUs on the cloud.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 35%Moat
top 38%Patents
top 45%Talent
bottom 49%Innovation
bottom 48%Tech
bottom 46%Funding: Raised $12.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (May 2026)
Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents
Patents: 9 patents matched (strict assignee match) · 9 filings since 2022 vs 0 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- May 2026Series B$12M
Founders & team
Investors
10D, Entree Capital, Connecticut Innovations, PhiFund Ventures, Harel T E C Partnership
Tech stack
BootstrapCalendlyGoogle CloudGoogle Cloud CdnGoogle WorkspaceGsap
#7
Series D · Tel Aviv, Tel Aviv · founded 2014 · 124 employees$115Mraised▾
Series D · Tel Aviv, Tel Aviv · founded 2014 · 124 employees
Developer of digital imaging platforms for hematology. The company uses computational photography to capture high-resolution (100X) full-field images of peripheral blood smears (PBS) and bone marrow aspirates (BMA), allowing labs to analyze entire slides without losing resolution or field of view.
Fliar Intelligence Index™ 83how this company ranks against its industry peers
AI
top 15%Funding
top 19%Product
top 21%Moat
top 28%Tech
top 29%Patents
top 31%AI: Holds AI/ML patents (G06N-family CPC)
Funding: Raised $115M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) · Last round Series D (Jul 2025)
Product: 6 distinct product lines · Company stage: Series D
Audience (LinkedIn): 30k LinkedIn followers — 8.4% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 awards announced in 12 mo
Funding rounds
- Jul 2025Series D$10M
- Jul 2024Series D$42M
- Sep 2022Conventional Debt$15M
- Feb 2022Series C$50M
Investors
Aurum Ventures, OTV, Kreos Capital, OurCrowd, Ilex Medical, Lrinstitutes
Tech stack
AddtoanyAddtoany Share ButtonsAmazon Web ServicesApple Icloud MailCdnjsCloudflare
#8
Public · Ness Ziona, Center District · founded 2004 · 73 employees$16.3Mraised▾
Public · Ness Ziona, Center District · founded 2004 · 73 employees
Developer of recombinant human collagen for regenerative medicine and aesthetics. It focuses on creating technologies and products for tissue regeneration and organ manufacturing. The company's plant-based technology enables the production of recombinant human type I collagen. This collagen is identical to that produced by the human body. The company develops products aimed at bioprinting tissues and organs and medical aesthetics.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Patents
top 22%Funding
top 26%Product
top 26%Tech
top 35%Moat
top 35%Innovation
top 43%Patents: 170 patents matched (strict assignee match) · 41 filings since 2022 vs 46 in 2017-21 · Latest publication 2026
Funding: Raised $16.3M across 11 rounds · 11 rounds over 20 yrs (0.6/yr) · Last round Post IPO (Feb 2026)
Product: 1 product launch event in 12 mo · Company stage: Public
Funding rounds
- Feb 2026Post IPO$4M
- Feb 2020Post IPO$4.5M
- Sep 2019Post IPO$5.5M
- Nov 2017Post IPO$2M
Investors
Invesco, Alpha Capital Partners, Docor, Pontifax, Rocky Point Ventures
Tech stack
Apache Http ServerBootstrapCloudflareCloudflare Bot ManagementComplianzContact Form 7
#9
Series A · Be er Sheva, South District · founded 2014 · 27 employees$9.3Mraised▾
Series A · Be er Sheva, South District · founded 2014 · 27 employees
Fize Medical develops a device for monitoring health status through urine. The company has developed a solution for real-time monitoring of urine production. Based on patented technology the solution is comprised of a platform and a module for measuring urine output.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Talent
top 38%Funding
top 42%Tech
top 42%Growth
top 45%Moat
top 48%Market
bottom 38%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $9.3M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) · Last round Series A (Mar 2026)
Tech: 33 technologies across 4/8 capability areas · Cloud: Cloudflare · Devops: Nginx
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Asahi Kasei Medical) announced in 12 mo
Funding rounds
- Mar 2026Series A$6M
- Dec 2024Series A$16M
- Dec 2021Series A$4M
- Apr 2021Series A$3.3M
Founders & team
Investors
Rapha Capital Management, Mendham Investment Group, Valites, eHealth Ventures, Hibiscus Capital Management, Teshuva Capital
Tech stack
CdnjsCloudflareCloudflare Bot ManagementContact Form 7Core-JsElementor
#10
Series A · Herzliya, Tel Aviv · founded 2012$11Mraised▾
Series A · Herzliya, Tel Aviv · founded 2012
Neurolief is focussed on developing a wearable platform technology for brain neuromodulation. It is developing a wearable device that enables the safe and effective treatment for neuro disorders such as migraine and depression without interfering with the patient's daily activities. As of September 2016, the device is in clinical development.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Patents
top 36%Talent
top 38%Innovation
top 39%Funding
top 46%Product
top 47%Moat
top 47%Patents: 55 patents matched (strict assignee match) · 18 filings since 2022 vs 29 in 2017-21 · Latest publication 2026
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Innovation: 55 patents (top 28% of patent-holders) · 18 filings since 2022 vs 29 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 7k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Market Access Professional
Funding rounds
- Mar 2026Series A$6M
- Aug 2025Series A$5M
- 2015Seed—
Founders & team
Investors
Terra Venture Partners, Brainsway, KT Squared, Champel Capital
#11
Public · Petah Tikva, Central District · founded 2008 · 69 employees$96.7Mraised▾
Public · Petah Tikva, Central District · founded 2008 · 69 employees
PolyPid has developed a technology platform (PLEX-Polymer-Lipid Encapsulation matriX) that enables a controlled and prolonged release of any active pharmaceutical ingredients (API). Its technology combines polymers and lipids, enabling small-and-large API entrapment in degradation and hydration protected environments, regardless of their chemical or physical characteristics. It allows the release of the API from the reservoir at pre-determined rates of up to several months, with a constant release rate. Its pipeline includes D-PLEXantibiotic drug reservoir designed to be implanted during surgery to prevent or treat surgical site infections (SSIs)), Bonypid-1000 (an antibiotic designed for bone related infections applications) and Bonypid-500 (an antibiotic eluting bone graft substitute intended to fill, augment or reconstruct periodontal or oral/maxillofacial defects while protecting from infections)
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 18%Moat
top 29%Patents
top 38%Tech
top 39%Innovation
top 46%Growth
top 48%Funding: Raised $96.7M across 10 rounds · 10 rounds over 14 yrs (0.7/yr) · Last round Post IPO (Jun 2025)
Moat: Editorial + unicorn rating 6/10 · IP moat: 138 patents · 9 curated direct competitors tracked
Patents: 138 patents matched (strict assignee match) · 26 filings since 2022 vs 55 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Jun 2025Post IPO$26.7M
- Dec 2024Post IPO$14.5M
- Aug 2024Post IPO$14.2M
- Jan 2024Post IPO$35M
Investors
Shavit Capital, Aurum Ventures, Yellin Lapidot, Xenia Venture Capital, Financiere Saint James, Regah Ventures
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAddtoanyAddtoany Share ButtonsAdobe AnalyticsAdobe Experience Platform Identity Service
#12
Public · Haifa, Haifa District · founded 2020$7.2Mraised▾
Public · Haifa, Haifa District · founded 2020
Developer of drugs for neurological disorders. It biologically-guided exosome therapy based on ExoTherapy platform technology for the treatment of acute spinal cord injury. It use exosomes as nanocarriers to deliver drug for neuron rewiring and regeneration.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 36%Tech
top 36%Talent
top 38%News
top 46%Growth
top 47%Market
bottom 29%Funding: Raised $7.2M across 9 rounds · 9 rounds over 2 yrs (4.5/yr) · Last round Post IPO (Mar 2026)
Tech: 34 technologies across 5/8 capability areas · Cloud: Akamai · Devops: Nginx
Talent: 1 named leader on record · 1 C-suite/founder profile curated · 6 leadership moves in 12 mo
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. ExoLyra) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$279.9K
- Aug 2025Post IPO$147.8K
- Apr 2025Post IPO$1.6M
- Jan 2025Post IPO$434.5K
Founders & team
Tech stack
CookieyesCore-JsDraftpress HfcmElementorGoogle Font ApiGoogle Tag Manager
Funding & investor landscape
$8.5Btotal disclosed funding
395companies funded
946disclosed rounds
6rounds last 90 days
Most active investors
Notable founders
Dan Lemaitre
Chairman & CEO · BlueWind Medical
Orahn Preiss Bloom
Founder & President · Ossio
Brian Verrier
CEO · Ossio
Chaim Lebovits
Chief Executive Officer · BrainStorm Cell
Yehuda Bachar
Founder · Butterfly Medical
Idan Geva
Ceo · Butterfly Medical
Uri Tal
Co-Founder · Vortex Imaging
Noam Levine
Founder & CTO · Fize Medica
Dror Zerem
CEO · Fize Medica
Shmuel Shany
Co-Founder · Neurolief
Scott Drees
CEO · Neurolief
Lior Shaltiel
Chief Executive Officer · NurExone
Prism market signals · Israel · country-scoped Prism corpus, 1,211,671 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · Israel
How research on Biotechnology is moving in Israel
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 267 Israel-affiliated papers.
top research entities
- Ministry of Agriculture118
- Hebrew University of Jerusalem29
- Agricultural Research Organization25
- Tel Aviv University21
- Ben-Gurion University of the Negev19
leading researchers
Itamar Willner · Dombrovsky, A. · Wei Zhao · Goor Sasson · Roy Novoselsky · Shalev Itzkovitz · Xiaoqing Liu · Hengyou Zhang
▲
Breakthroughs69 · 26%
▲ 0%→25% share
0 median citations80% since 2021mostly empirical
Gene research newly emerged with 10 papers, alongside Transcription factor and Mutant, driving Breakthroughs from 0% to 25% field-share.
rising sub-themes (early→recent)
- Mitochondrion1→5
Newly emergingGene 0→10 · Transcription factor 0→5 · Mutant 0→5
Landmark The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity · 3,514 cites
◆
Advancements119 · 45%
▲ 0%→48% share
0 median citations90% since 2021mostly empirical
Gene papers surged 1→18 and Transcriptome, Microbiome newly emerged, lifting Advancements to 48% field-share.
rising sub-themes (early→recent)
- Gene1→18
- Plant disease resistance1→7
- Resistance (ecology)2→6
Newly emergingTranscriptome 0→8 · Microbiome 0→8 · Selection (genetic algorithm) 0→7
Landmark Plant Growth-Promoting Rhizobacteria: Context, Mechanisms of Action, and Roadmap to Commercialization of Biostimulants f · 1,849 cites
▼
Concerns43 · 16%
▲ 0%→14% share
0 median citations74% since 2021mostly reviews
Agriculture concern papers doubled (3→6) as Concerns field-share rose from 0% to 14%.
rising sub-themes (early→recent)
- Agriculture3→6
Landmark Genetic Engineering for Modern Agriculture: Challenges and Perspectives · 1,148 cites
RESEARCH HOTSPOTS · Israel
Where biotechnology is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Jerusalem29 · +0.39
Tel Aviv27 · +0.41
Beer Sheva19 · +0.60
Haifa17 · +0.40
Rehovot16 · +0.53
Common questions
How many Life Sciences companies are there in Israel?
Radar tracks 1290 indexable Life Sciences companies headquartered in Israel that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Israel?
The Life Sciences companies in Israel on this list have raised a combined $8.5B in disclosed equity funding across 395 funded companies.
Which is the highest-funded Life Sciences company in Israel?
Insightec is the highest-funded Life Sciences company in Israel, with $574.2M in disclosed equity funding.
How many Life Sciences companies in Israel are funded?
395 of the 1290 Life Sciences companies in Israel on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Israel?
2 Life Sciences companies in Israel on this list are valued at $1B or more.
Who are the top investors in Israel Life Sciences companies?
The most active investors in Israel Life Sciences companies on this list include Europa, EIC Fund, The Trendlines Group, MassChallenge, Pontifax.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.